NP
REGN icon

NorthRock Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

NorthRock Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,943
Closed -$1.09M – 856
2025
Q3 		$1.09M Buy
1,943
+1,069
+122% +$604K 0.02% 327
2025
Q2 		$459K Buy
874
+166
+23% +$92.7K 0.01% 424
2025
Q1 		$449K Sell
708
-94
-12% -$64.7K 0.02% 370
2024
Q4 		$571K Sell
802
-156
-16% -$131K 0.02% 323
2024
Q3 		$1.01M Buy
958
+235
+33% +$262K 0.03% 211
2024
Q2 		$760K Buy
723
+64
+10% +$62K 0.03% 238
2024
Q1 		$634K Buy
659
+20
+3% +$19K 0.02% 299
2023
Q4 		$561K Buy
639
+390
+157% +$321K 0.02% 293
2023
Q3 		$205K Buy
+249
New +$196K 0.02% 334
2023
Q2 		– Sell
-349
Closed -$287K – 341
2023
Q1 		$287K Sell
349
-17
-5% -$12.8K 0.03% 228
2022
Q4 		$264K Buy
+366
New +$270K 0.03% 271
2021
Q4 		– Sell
-589
Closed -$356K – 355
2021
Q3 		$356K Buy
+589
New +$366K 0.03% 195

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

NorthRock Partners's REGN Position: Q4 2025 in Review

NorthRock Partners sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 1,943 shares — an estimated $1.09M sold.

NorthRock Partners first reported a position in REGN in Q3 2021 and held it in 12 quarters. The position peaked at $1.09M in Q3 2025. 1,385 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • NorthRock Partners reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • NorthRock Partners sold 1,943 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $1.09M.
  • NorthRock Partners first reported a position in Regeneron Pharmaceuticals in Q3 2021 and held it in 12 quarters.
  • NorthRock Partners's Regeneron Pharmaceuticals position peaked at $1.09M in Q3 2025.
  • 1,385 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on NorthRock Partners's 13F filing for Q4 2025, filed 17 Feb 2026.